Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Operations (2016 - 2025)

Ligand Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 45915000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 61.27% year-over-year to 45915000.0; the TTM value through Dec 2025 reached 85471000.0, down 11.93%, while the annual FY2025 figure was 49359000.0, 49.14% down from the prior year.
  • Cash from Operations for Q4 2025 was 45915000.0 at Ligand Pharmaceuticals, up from 25445000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 53472000.0 in Q4 2022 and bottomed at 25445000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 20201000.0 (2021), against an average of 21319000.0.
  • The largest annual shift saw Cash from Operations surged 16336.59% in 2024 before it tumbled 235.84% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 27642000.0 in 2021, then soared by 93.44% to 53472000.0 in 2022, then plummeted by 84.92% to 8065000.0 in 2023, then skyrocketed by 253.02% to 28471000.0 in 2024, then soared by 61.27% to 45915000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cash from Operations are 45915000.0 (Q4 2025), 25445000.0 (Q1 2025), and 28471000.0 (Q4 2024).